Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
“Sales of Teribone Can Reach ¥10 Bil.”: President Asano of Asahi Kasei Pharma
Asahi Kasei Pharma will aggressively promote Teribone (teriparatide), a treatment for osteoporosis approved in September, in the growing osteoporosis market. In a press conference in Tokyo on October 24, President and Representative Director Toshio Asano said that sales of Teribone…
To read the full story
BUSINESS
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
- Furukawa Resigns as Heartseed Outside Director
September 18, 2026
- Japan Approves Fuji’s New Stelara, Simponi Biosimilar Formulations
September 17, 2026
- Maruishi Clinches Japan Rights to Kringle’s Vocal Fold Scar Drug
September 17, 2026
- Nobelpharma, Fuso to Co-Promote Hypozincemia Drug Zintus
September 17, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…